Marketscan claims data study assessed fall risk in 57 086 older adult starting gabapentin vs duloxetine & found gabapentin was not associated with increase in falls. At 6-mos, gabapentin had lower risk of falls (HR 0.52; 0.43 to 0.64]. https://t.co/agrdzkxNdL https://t.co/Te981iDMZU

Nipocalimab, a mAb that blocks FcRn, was granted a Priority Review from the FDA. J&J has submitted Biologics License Application (BLA) for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) myasthenia gravis based on Phase 3 Vivacity-MG3 study.… https://t.co/6sVbrgTBvF https://t.co/9a1dBWz87R

Does Colchicine Lower Gout Mortality Risk? Data from a large UK database finds that gout patients starting urate-lowering therapy (ULT) will benefit from added colchicine prophylaxis by having fewer cardiovascular events. https://t.co/89BXT5OnVS https://t.co/N4IQzRpcPk

EULAR: Considerations when Transitioning from Pediatric to Adult Rheumatologic Care EULAR has established guidance on best practices for delivering patient education in physical activity and self-management of pain during transitional care in rheumatology.… https://t.co/eIqbIENFNV https://t.co/NWjiapEPvP

Prevalence of Autoimmune Diseases in the United States An epidemiologic assessment of the prevalence of autoimmune diseases in the United States (US) finds that nearly 5% of the population has an autoimmune disorder, twice as many in women compared to men.… https://t.co/L5BusRvcFP https://t.co/JTw8CXf1Tq

🚨 Just 4 weeks until #RheumNowLive 2025! 🚨 📅 Feb 8-9 | Dallas, TX Don’t miss 1.5 days of cutting-edge #rheumatology education, interactive sessions, and unmatched networking! 🧠 Expert insights: 🔹 EGPA care innovations (Dr. Wechsler) 🔹 Vasculitis imaging… https://t.co/ObHBj1dQoK https://t.co/UuDZxBhdLr

Study of 1032 adults > 50 yrs on dialysis compared denosumab vs or oral bisphosphonates. 3 yr results showed compared with oral bisphosphonates, denosumab lowered the risk for fractures by 45% and increased the risk for MACE by 36% https://t.co/evaTc8Ag5Y https://t.co/wps14UddgP

Anti-Zoster Drug Prevents Shingles in Lupus Patients on Anifrolumab The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with SLE under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential… https://t.co/zebERdPfzV https://t.co/MOIjbhcWSa

Post hoc study of Hidradenitis suppurativa (HS) phase 3 study w/ 588 pts rx w/ either PBO or adalimumab. 79% had elevated CRP. High CRP assoc w/ more severe HS, higher BMI (34 vs 28; P < .001), & lower odds of ADA response (OR 0.53). Activity or Obesity? https://t.co/ZQzumtW2LV https://t.co/FWaQMyP2TT

Real world observations from 65 RA-ILD pts Rx w/ nintendinb (95% on DMARDs/Pred) in Italian GISEA registry. 12 mos retention rate = 77% & was effective ~80% in pts w/ > 6 months F/U. Side effects in 55% (mainly GI) & ~1/2 had to reduce dose. 23% D/C drug for AE.… https://t.co/aVcIYtoMK4 https://t.co/CBHxzBc9XQ

Spanish registry ARTESER, looked at GCA outcomes from 2013 to 2019. In 1200 GCA pts ~ 2 yrs F/U, The 5-Yr mortality 37.9/1000 pt/yrs; higher in males vs females (59 vs 29 p<0.001), but was same as gen population . Incr mortality w/ age & male sex. HA & Hgb were protective… https://t.co/idnuUL9Kog https://t.co/2MsOxuTtCd

Review of of nurse-led care (NLC) vs Rheum-led (RLC) vs Usual care in RA pts - 14 studies, 3369 pts. shows NLC proves highly effective in managing RA patients, surpassing usual care and equating to rheumatologist-led care in primary and secondary outcomes.… https://t.co/evpFTT9n22 https://t.co/n8ncKG9SFt